

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



李氏大藥廠

## Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司\*

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 950)**

### **VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

On 28 January 2020, “Guidance Notes on the Public Protection of Pneumonia associated with the Latest Novel Coronavirus (2019-nCoV)” has been advised by National Health Commission of the People’s Republic of China and written and published by Chinese Center for Disease Control and Prevention for the prevention and control of the latest novel coronavirus (2019-nCoV) epidemic and in which Interferon has been included in the preventive therapy drug list for the pneumonia associated with the latest novel coronavirus (2019-nCoV). In addition, the Municipal Health Commissions such as in Wuhan and Shanghai have also listed Interferon as therapy drug thereof. As a result, Yallaferon® (Recombinant Human Interferon  $\alpha$ 2b Gel), the Group’s antiviral drug, has been admitted to the “Catalogue of Emergency Drug Manufacturer of Anhui Province” and “Key Medical Supply Support and Information Monitoring Platform of the Ministry of Industry and Information Technology of the People’s Republic of China” by the Department of Economic and Information Technology of Anhui Province, and becomes one of the critical materials for this epidemic prevention and control.

#### **ABOUT YALLAFERON®**

Yallaferon® is the proprietary product of the Group with patented technology and was launched in China market since 2001 and marked the beginning of a new era in the topical application of Interferon which is convenient to carry and does not need to be refrigerated. In October 2019, “Pharmacoeconomic Evaluation on Recombinant Human Interferon  $\alpha$ 2b Gel for the Treatment of High Risk Human Papillomavirus (HPV)” has been issued and published in “China Journal of Pharmaceutical Economics” Tenth issue, Volume 4, 2019,

which is the first topical Interferon in China to conduct the pharmacoeconomic evaluation of anti-HPV infection drugs. Yallaferon<sup>®</sup> is use for the treatment of viral infections of the skin such as genital warts, herpes zoster, genital herpes, cervical HPV infection and cervical ectropion, etc.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 3 February 2020

*\* For identification purpose only*

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Mr. Simon Miles Ball is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*